A Washington Post/Dr. Leana Wen newsletter highlights a growing trend of psychedelic microdosing in the U.S., with an estimated 10 million adults reportedly microdosing substances such as psilocybin, MDMA, and LSD, often to self‑treat depression, anxiety, or enhance focus. However, experts caution that microdosing lacks standardized definitions, oversight, or safety data, and unregulated products may contain unknown or unsafe compounds. A 2026 RAND report found no strong evidence of cognitive benefit, and scientists warn that unsupervised use may lead to adverse psychiatric effects or delay engagement with evidence‑based treatments. While clinical trials continue to explore therapeutic uses of psychedelics under controlled conditions, this trend underscores the need for better public education, regulation, and clear clinical guidelines to minimize potential harm and ensure patient safety.
Full Article: https://www.washingtonpost.com/opinions/2026/02/05/microdosing-psilocybin-psychedelics-depression/?utm